BioNanomatrix

Corporate Fact Sheet
Fall 2009

BioNanomatrix's revolutionary nanochannel technology enables rapid and cost-effective analysis of the human genome, delivering single-molecule sensitivity in a massively parallel format.

About BioNanomatrix

BioNanomatrix is developing unique nanoscale imaging and analytic platforms designed to dramatically reduce the time and cost needed to analyze the genome. The company's patented technology delivers comprehensive analyses of genomic and epigenomic information with single-molecule sensitivity, while avoiding the fragmentation and complex data reassembly required by other approaches.

This technology's affordability, speed and simplicity are expected to make the routine use of genetic information feasible in broad-ranging applications including biomedical research, genetic diagnostics and personalized medicine.

BioNanomatrix's development programs are partly supported by grants from the NIH and an $8.8 million award to jointly develop a platform capable of sequencing the human genome at a cost of just $100. The company is collaborating with commercialization partners for nearer-term applications.

Technology Platform



BioNanomatrix's pioneering technology enables nanoscale identification and analysis of the genome, delivering single-molecule sensitivity in a massively parallel format. It can uniquely detect and identify *individual long strands* of DNA, making it possible to survey the genome in its native state, in context and at ultra-high resolution, without the need for DNA amplification.

Key to its revolutionary technology is BioNanomatrix's patented nanochannels--tiny nanoscale channels incorporated in a nanochip fluidics device that separates and directs vast amounts of genetic information in a linear fashion and in sequence, one long strand at a time.

The design of the nanochip device makes it possible to conduct millions of these genetic analyses simultaneously, in a massively parallel fashion. The technology's ability to image very long individual strands of DNA is also expected to facilitate difficult but important analyses including structural variations, copy number variations and complex *de novo* and cancer genomic analyses.

The combination of these unique features enables BioNanomatrix to deliver highly accurate and informative genetic analyses more rapidly and cost effectively than existing technologies.

BioNanomatrix has licensed exclusive rights to its core technologies from Princeton University. The nanochannel technology being developed at BioNanomatrix is protected under one issued U.S. patent, with additional patents pending.

$100 GENOME PROJECT

BioNanomatrix and partner Complete Genomics Inc. were awarded an $8.8 million grant from NIST-ATP to develop a system capable of sequencing the human genome in 8 hours at a cost of less than $100. If successful, the $100 genome project could transform the role of genomics in medicine, making whole genome sequencing feasible for routine use in medical care and delivering far more diagnostic and predictive information than is available today.

Leadership Team

Michael Boyce-Jacino, Ph.D.
President & CEO

Han Cao, Ph.D.
Founder & CSO

Lorraine LoPresti, CPA
VP & CFO

Gary Zweiger, Ph.D.
VP Business Development

Michael Kochersperger
VP Engineering

Major Investors

Battelle Ventures
KT Venture Group
Ben Franklin Technology Partners
21Ventures

BioNanomatrix Contact

BioNanomatrix Inc.
3701 Market Street, 4th Floor
Philadelphia, PA 19104
(267) 499-2014

Media Contact

Barbara Lindheim
GendeLLindheim BioCom Partners
(212) 918-4650